Two Struggling Stocks Poised for a Potential Comeback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Should l Buy NVO?
Source: NASDAQ.COM
Novo Nordisk's Growth Potential: Novo Nordisk has several upcoming catalysts, including late-stage studies for CagriSema and a potential oral semaglutide formulation, which could significantly boost its revenue and market position.
Regeneron's Resilience: Despite facing biosimilar competition for Eylea, Regeneron has shown strong financial results, with a 1% revenue growth and promising developments in its product pipeline, including Dupixent and a new cancer therapy, Lynozyfic.
Investment Opportunities: Both Novo Nordisk and Regeneron are considered attractive investment options due to their potential for recovery and growth, especially as Novo Nordisk's stock is currently undervalued.
Stock Advisor Recommendations: The Motley Fool's Stock Advisor has identified other stocks as top picks, suggesting that while Novo Nordisk is recommended, it did not make the top 10 list, which has historically yielded significant returns for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 39.320
Low
42.00
Averages
54.67
High
70.00
Current: 39.320
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Wegovy Approved for Obesity Treatment
- Regulatory Approval: The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk's single-dose 7.2mg semaglutide (Wegovy) for treating adult patients with obesity, defined as having a body mass index (BMI) of 30kg/m² or higher, marking a significant expansion in the company's obesity treatment portfolio.
- Dosage Advantage: This 7.2mg dose is administered via a single injection to provide the maximum weekly dose, aimed at assisting obese patients in weight loss and management, thereby enhancing patient convenience and adherence to treatment.
- Market Competition: Novo Nordisk and Eli Lilly are key players in the GLP-1 drug market, and while NVO shares rose 2.6% in premarket trading, the company faces intense competition and potential risks that could impact its market position.
- Usage Limitations: The drug is not applicable for overweight patients with a BMI below 30kg/m² and is not intended for those using Wegovy to reduce the risk of serious heart problems, which may affect its market acceptance and sales potential.
See More
Eli Lilly vs. Novo Nordisk Market Performance Comparison
- Market Value Comparison: Three years ago, Eli Lilly and Novo Nordisk had similar market values, but Eli Lilly surpassed $1 trillion last year, despite recent momentum loss, indicating its strong market performance and competitive edge.
- Product Competitive Advantage: Eli Lilly's Zepbound demonstrated an average weight loss of 20.2% in clinical trials against Novo Nordisk's Wegovy, which achieved only 13.7%, allowing Eli Lilly to lead the anti-obesity market and likely maintain this advantage going forward.
- Pipeline Potential: Eli Lilly's retatrutide showed an impressive 28.7% mean weight loss in a 68-week phase 3 study while alleviating knee pain, further solidifying its leadership in the weight loss drug market.
- Future Growth Outlook: Although Novo Nordisk faced setbacks in clinical trials, its robust pipeline still holds promise, and with a forward P/E of 11.2, it presents an attractive valuation that could yield significant returns for investors.
See More
Competitive Analysis of Eli Lilly and Novo Nordisk
- Market Leadership: Eli Lilly's Zepbound demonstrated an average weight loss of 20.2% over 72 weeks in clinical trials, significantly outperforming Novo Nordisk's Wegovy at 13.7%, establishing Eli Lilly as the leader in the anti-obesity market with expectations to maintain this advantage.
- Pipeline Strength: Eli Lilly's retatrutide showed an impressive 28.7% weight loss in a 68-week phase 3 study and is expected to gain approval in the coming years, further solidifying its leadership in the weight loss drug market and driving strong financial performance.
- Challenges for Novo Nordisk: Novo Nordisk's CagriSema underperformed in phase 3 studies and failed to surpass Zepbound, with its anti-obesity drug portfolio lagging behind Eli Lilly's, potentially impacting its market share and future growth prospects.
- Valuation Appeal: Despite Novo Nordisk's robust pipeline in anti-obesity drugs, its forward P/E ratio of 11.2 is below the healthcare sector average of 17.2, presenting a relatively attractive buying opportunity for investors, especially if upcoming new products can enhance sales and profits.
See More
NASDAQ 100 Pre-Market Indicator Declines
- Market Indicator Decline: The NASDAQ 100 Pre-Market Indicator fell by 10.78 points to 25,831.22, reflecting cautious market sentiment that may influence short-term investor decisions.
- Active Stock Performance: Snap Inc. (SNAP) rose by $0.39 in pre-market trading, with a volume of 12,612,698 shares traded, currently priced at $5.99, indicating market expectations for its future performance.
- IonQ Stock Recommendation: IonQ, Inc. (IONQ) increased by $2.57 to $38.33, with 5,355,699 shares traded, and Zacks reports its average recommendation is in the “buy range,” suggesting analysts are optimistic about its prospects.
- Oracle Stock Dynamics: Oracle Corporation (ORCL) gained $2.01 to $165.01, with a trading volume of 1,524,659 shares, and Zacks analysts also recommend it in the “buy range,” reflecting market confidence in its continued growth.
See More
U.S. Farmers Face Pressure from Soaring Fertilizer Prices
- Fertilizer Price Surge: Fertilizer costs have skyrocketed from $139 per acre last year to $217 this season due to shipping disruptions from the Middle East conflict, forcing farmers to cut back on inputs, which could impact the supply of certain crops in the U.S. and globally.
- Deteriorating Financial Conditions: A survey by the American Farm Bureau reveals that 58% of farmers report worsening financial conditions, with 78% of Southern farmers unable to afford necessary fertilizer, highlighting severe challenges in agricultural production.
- Planting Strategy Adjustments: In response to soaring fertilizer costs, farmers like Lorenda Overman plan to reduce corn acreage and shift to less fertilizer-dependent soybeans to mitigate cost pressures and protect profit margins.
- Increased Yield Risks: The reduction in fertilizer use and changes in planting strategies raise the risk of lower crop yields for 2026, prompting the Farm Bureau to advocate for more aid from the White House to assist farmers facing rising production costs.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
Novo Nordisk's Wegovy Approved for Obesity Treatment
- Regulatory Approval: The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk's single-dose 7.2mg semaglutide (Wegovy) for treating adult patients with obesity, defined as having a body mass index (BMI) of 30kg/m² or higher, marking a significant expansion in the company's obesity treatment portfolio.
- Dosage Advantage: This 7.2mg dose is administered via a single injection to provide the maximum weekly dose, aimed at assisting obese patients in weight loss and management, thereby enhancing patient convenience and adherence to treatment.
- Market Competition: Novo Nordisk and Eli Lilly are key players in the GLP-1 drug market, and while NVO shares rose 2.6% in premarket trading, the company faces intense competition and potential risks that could impact its market position.
- Usage Limitations: The drug is not applicable for overweight patients with a BMI below 30kg/m² and is not intended for those using Wegovy to reduce the risk of serious heart problems, which may affect its market acceptance and sales potential.
See More
Eli Lilly vs. Novo Nordisk Market Performance Comparison
- Market Value Comparison: Three years ago, Eli Lilly and Novo Nordisk had similar market values, but Eli Lilly surpassed $1 trillion last year, despite recent momentum loss, indicating its strong market performance and competitive edge.
- Product Competitive Advantage: Eli Lilly's Zepbound demonstrated an average weight loss of 20.2% in clinical trials against Novo Nordisk's Wegovy, which achieved only 13.7%, allowing Eli Lilly to lead the anti-obesity market and likely maintain this advantage going forward.
- Pipeline Potential: Eli Lilly's retatrutide showed an impressive 28.7% mean weight loss in a 68-week phase 3 study while alleviating knee pain, further solidifying its leadership in the weight loss drug market.
- Future Growth Outlook: Although Novo Nordisk faced setbacks in clinical trials, its robust pipeline still holds promise, and with a forward P/E of 11.2, it presents an attractive valuation that could yield significant returns for investors.
See More
Competitive Analysis of Eli Lilly and Novo Nordisk
- Market Leadership: Eli Lilly's Zepbound demonstrated an average weight loss of 20.2% over 72 weeks in clinical trials, significantly outperforming Novo Nordisk's Wegovy at 13.7%, establishing Eli Lilly as the leader in the anti-obesity market with expectations to maintain this advantage.
- Pipeline Strength: Eli Lilly's retatrutide showed an impressive 28.7% weight loss in a 68-week phase 3 study and is expected to gain approval in the coming years, further solidifying its leadership in the weight loss drug market and driving strong financial performance.
- Challenges for Novo Nordisk: Novo Nordisk's CagriSema underperformed in phase 3 studies and failed to surpass Zepbound, with its anti-obesity drug portfolio lagging behind Eli Lilly's, potentially impacting its market share and future growth prospects.
- Valuation Appeal: Despite Novo Nordisk's robust pipeline in anti-obesity drugs, its forward P/E ratio of 11.2 is below the healthcare sector average of 17.2, presenting a relatively attractive buying opportunity for investors, especially if upcoming new products can enhance sales and profits.
See More
NASDAQ 100 Pre-Market Indicator Declines
- Market Indicator Decline: The NASDAQ 100 Pre-Market Indicator fell by 10.78 points to 25,831.22, reflecting cautious market sentiment that may influence short-term investor decisions.
- Active Stock Performance: Snap Inc. (SNAP) rose by $0.39 in pre-market trading, with a volume of 12,612,698 shares traded, currently priced at $5.99, indicating market expectations for its future performance.
- IonQ Stock Recommendation: IonQ, Inc. (IONQ) increased by $2.57 to $38.33, with 5,355,699 shares traded, and Zacks reports its average recommendation is in the “buy range,” suggesting analysts are optimistic about its prospects.
- Oracle Stock Dynamics: Oracle Corporation (ORCL) gained $2.01 to $165.01, with a trading volume of 1,524,659 shares, and Zacks analysts also recommend it in the “buy range,” reflecting market confidence in its continued growth.
See More
U.S. Farmers Face Pressure from Soaring Fertilizer Prices
- Fertilizer Price Surge: Fertilizer costs have skyrocketed from $139 per acre last year to $217 this season due to shipping disruptions from the Middle East conflict, forcing farmers to cut back on inputs, which could impact the supply of certain crops in the U.S. and globally.
- Deteriorating Financial Conditions: A survey by the American Farm Bureau reveals that 58% of farmers report worsening financial conditions, with 78% of Southern farmers unable to afford necessary fertilizer, highlighting severe challenges in agricultural production.
- Planting Strategy Adjustments: In response to soaring fertilizer costs, farmers like Lorenda Overman plan to reduce corn acreage and shift to less fertilizer-dependent soybeans to mitigate cost pressures and protect profit margins.
- Increased Yield Risks: The reduction in fertilizer use and changes in planting strategies raise the risk of lower crop yields for 2026, prompting the Farm Bureau to advocate for more aid from the White House to assist farmers facing rising production costs.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
